US OptionsDetailed Quotes
BCTX241220P2000
- 0.00
- 0.000.00%
15min DelayClose Nov 29 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover382.49%IV-103.67%PremiumDec 20, 2024Expiry Date1.02Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6466Delta0.4349Gamma0.85Leverage Ratio-0.0083Theta-0.0008Rho-0.55Eff Leverage0.0008Vega
BriaCell Therapeutics Stock Discussion
Sign in to post a comment
$BriaCell Therapeutics (BCTX.US)$
Something brewing ?
Something brewing ?
1
$BriaCell Therapeutics (BCTX.US)$
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
SABCS® "Spotlight" poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer patient subtypes
Median overall survival of 13.4 months exceeds historical controls. Phase 2 final median overall survival calcula...
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
SABCS® "Spotlight" poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer patient subtypes
Median overall survival of 13.4 months exceeds historical controls. Phase 2 final median overall survival calcula...
$BriaCell Therapeutics (BCTX.US)$ BriaCell 2024 SABCS Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
GlobeNewswire· 6 mins
SABCS "Spotlight" poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer patient subtypes Median overall survival of 13.4 months exceeds historical controls. Phase 2 final median o...
GlobeNewswire· 6 mins
SABCS "Spotlight" poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer patient subtypes Median overall survival of 13.4 months exceeds historical controls. Phase 2 final median o...
$BriaCell Therapeutics (BCTX.US)$ Reuters
2 mins ago
Briacell Announces First Patient Dosed With Bria-Ots™ in Metastatic Breast Cancer Study
2 mins ago
Briacell Announces First Patient Dosed With Bria-Ots™ in Metastatic Breast Cancer Study
5
$BriaCell Therapeutics (BCTX.US)$ Low risk at these prices. I can place my SLO below 0.45 or 0.40. This is very oversold and showing Bullish Divergence imo.
1
$BriaCell Therapeutics (BCTX.US)$ ok what's up why it fall
1
$BriaCell Therapeutics (BCTX.US)$ BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
1 MINUTE AGO, 7:50 AM EST
VIA GLOBENEWSWIRE
BriaCell's clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in preclinical models
Novel therapy activates both innate and adaptive immune systems
Proof of concept Phase 1/2 Study of Bria-BRES™ in met...
1 MINUTE AGO, 7:50 AM EST
VIA GLOBENEWSWIRE
BriaCell's clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in preclinical models
Novel therapy activates both innate and adaptive immune systems
Proof of concept Phase 1/2 Study of Bria-BRES™ in met...
1
$BriaCell Therapeutics (BCTX.US)$ BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
3 MINUTES AGO, 7:50 AM EDT
VIA GLOBENEWSWIRE
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell's Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients
Multiple outperforming patients with overall survival of over 2 years
Survival benefit observed even in heavily pre-treated patients w...
3 MINUTES AGO, 7:50 AM EDT
VIA GLOBENEWSWIRE
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell's Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients
Multiple outperforming patients with overall survival of over 2 years
Survival benefit observed even in heavily pre-treated patients w...
6
$BriaCell Therapeutics (BCTX.US)$
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
▪️55% of BriaCell patients1 remained alive one year since enrollment in BriaCell's Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients
▪️Multiple outperforming patients with overall survival of over 2 years
▪️Survival benefit observed even in heavily pre-treated patients who failed treatment with checkpoint inhib...
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
▪️55% of BriaCell patients1 remained alive one year since enrollment in BriaCell's Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients
▪️Multiple outperforming patients with overall survival of over 2 years
▪️Survival benefit observed even in heavily pre-treated patients who failed treatment with checkpoint inhib...
3
1
No comment yet
Willy 5150 : could be, but it's better to focus on Price Action. Atm looks like a good stock to swing trade as it looks like it's bottoming out. Just my silly and humble opinion.